Transforming Cancer Care through Strategic Collaborations
In a promising advancement for healthcare, Massive Bio, a leader in AI-driven clinical trial matching, has teamed up with Foundation Medicine, Inc. This collaboration seeks to broaden access to innovative clinical trials for cancer patients. By combining Massive Bio’s state-of-the-art patient matching technology with Foundation Medicine’s deep expertise in next-generation sequencing (NGS), both organizations are set to change the face of oncology clinical trials.
Addressing the Enrollment Challenge in Oncology Trials
One major hurdle in the medical field is the low participation rate in oncology clinical trials, which remains around 8% among eligible patients. This figure highlights the urgency of the issue, especially as new treatments increasingly target rare cancers. Alarmingly, around 80% of clinical studies across the globe find it challenging to recruit enough patients within the deadlines set by biopharmaceutical companies. This partnership aims to overcome these obstacles by integrating solutions that improve service delivery through a shared focus on data and AI analytics designed to connect patients with the right trials.
Using AI for Personalized Treatment Plans
Dr. Arturo Loaiza-Bonilla, MD MSEd, Co-founder and Chief Medical Officer at Massive Bio, shared, "Real-time AI applications and our expansive data significantly enhance the speed and accuracy of clinical trial matching.” This breakthrough technology allows for quicker and more precise individualized treatments, greatly improving patient outcomes. By collaborating closely with Foundation Medicine, Massive Bio hopes to address persistent issues in clinical trial enrollment, often referred to as the cancer clinical trial enrollment paradox.
Expanding Massive Bio’s Network
Massive Bio is building a broad global network focused on oncology and hematology, aiming to significantly enhance patient recruitment on a large scale. Currently, the platform operates with a network of over 132,000 patients and 5,000 physicians, alongside partnerships with 40 pharmaceutical and CRO clients. Central to their mission is Synergy-AI, a responsive AI platform that processes and summarizes extensive medical records, including biomarker data, to instantly match patients with over 16,000 clinical trials. This technological advantage not only maximizes enrollment potential but also significantly lowers the number of screen failures, a crucial step for furthering cancer research.
Collaboration for Greater Patient Access
Through this partnership, Massive Bio and Foundation Medicine are committed to increasing clinical trial enrollment by leveraging their unique networks and advanced capabilities within healthcare. Their combined efforts will employ cutting-edge AI strategies, along with a robust digital health platform, refining clinical trial processes and ultimately enhancing the precision of oncology treatments.
Empowering Patients through Genomic Profiling
Heather Jorajuria, Senior Vice President of Clinical & Scientific Operations at Foundation Medicine, highlights the company's dedication to empowering healthcare providers. "In addition to offering high-quality genomic profiling to aid informed decision-making, we strive to pinpoint personalized treatment options, which encompass clinical trials." Their collaboration with Massive Bio ensures that patients remain central to the process, utilizing their shared expertise and resources to boost access to critical clinical studies.
About Massive Bio
Massive Bio envisions reshaping the pharmaceutical value chain by providing innovative solutions that make the transition from drug development to commercialization seamless. As a unique, AI-enabled real-world data company, it addresses various challenges faced along the patient journey, enhancing accessibility to advanced treatment options and improving the management of clinical trials for pharmaceutical firms. Founded in 2015 by a diverse group of clinical, technology, and M&A professionals, Massive Bio has made a significant impact on over forty pharmaceutical companies, contract research organizations, and hospital networks. They are recognized as a founding member of the CancerX public-private partnership and actively engage in initiatives like the Cancer Moonshot. With a strong global presence, Massive Bio is continually expanding its influence, with over 100 employees across 17 countries. For more about their groundbreaking efforts, visit www.massivebio.com and follow them on social media.
Frequently Asked Questions
What’s the main aim of the collaboration between Massive Bio and Foundation Medicine?
The partnership is designed to improve patient access to clinical trials and enhance enrollment rates by utilizing AI-driven matching technologies.
How does Massive Bio's technology assist in matching patients to clinical trials?
Massive Bio employs an AI-driven platform named Synergy-AI, which analyzes extensive medical records to efficiently match patients with relevant clinical trials.
Why is low enrollment in clinical oncology trials concerning?
With only about 8% of eligible patients participating in these trials, it poses a significant challenge for developing effective treatments for various cancer types, especially rare ones.
What is the expected impact of implementing advanced AI techniques?
By utilizing advanced AI methods, the aim is to simplify clinical trial processes, enhance matching precision, and ultimately improve patient outcomes in oncology treatments.
What future vision does Massive Bio have for cancer treatments?
Massive Bio's vision focuses on transforming the entire pharmaceutical value chain, facilitating a smooth transition from drug development to commercialization while also improving access to clinical trials and making treatment decisions more effective through real-world data.
